Antithrombotic drugs, patient characteristics, and gastrointestinal bleeding: Clinical translation and areas of research

Blood Reviews

Volumn 29, Issue 5, 2015, Pages 335-343

  Di Minno, Alessandro ^a   Spadarella, Gaia ^a   Prisco, Domenico ^b   Scalera, Antonella ^a   Ricciardi, Elena ^a   Di Minno, Giovanni ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Antithrombotic drugs; Co morbidities; Gastrointestinal bleeding; Patient characteristics; Therapeutic context

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; APIXABAN; CLOPIDOGREL; CORTICOSTEROID; DABIGATRAN; EDOXABAN; NONSTEROID ANTIINFLAMMATORY AGENT; PRASUGREL; PROTON PUMP INHIBITOR; RIVAROXABAN; TICAGRELOR; WARFARIN;

ACUTE CORONARY SYNDROME; ANTICOAGULANT THERAPY; ARTICLE; BRAIN HEMORRHAGE; COMORBIDITY; CORONARY ARTERY DISEASE; DEEP VEIN THROMBOSIS; DISEASE SEVERITY; DIVERTICULITIS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; GASTROINTESTINAL HEMORRHAGE; HUMAN; LOW DRUG DOSE; LUNG EMBOLISM; PEPTIC ULCER; PREVALENCE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; TREATMENT DURATION; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM; GASTROINTESTINAL DISEASE; HEMORRHAGE;

ANTICOAGULANTS; COMORBIDITY; GASTROINTESTINAL DISEASES; HEMORRHAGE; HUMANS;

EID: 84941258889     PISSN: 0268960X     EISSN: 15321681     Source Type: Journal    
DOI: 10.1016/j.blre.2015.03.004     Document Type: Article

References (99)

1. Lanas A., García-Rodríguez L.A., Polo-Tomás M., Ponce M., Alonso-Abreu I., Perez-Aisa M.A., et al. Time trends and impact of upper and lower gastrointestinal bleeding and perforation in clinical practice. Am J Gastroenterol 2009, 104(7):1633-1641.
2. Parker D.R., Luo X., Jalbert J.J., Assaf A.R. Impact of upper and lower gastrointestinal blood loss on healthcare utilization and costs: a systematic review. J Med Econ 2011, 14(3):279-287.
3. Desai J., Kolb J.M., Weitz J.I., Aisenberg J. Gastrointestinal bleeding with the new oral anticoagulants-defining the issues and the management strategies. Thromb Haemost 2013, 110(2):205-212.
4. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, MI, and stroke in high risk patients. BMJ 2002, 324:71-86. Antithrombotic Trialists' Collaboration.
5. Hallas J., Dall M., Andries A., Andersen B.S., Aalykke C., Hansen J.M., et al. Use of single and combined antithrombotic therapy and risk of serious upper gastrointestinal bleeding: population based case-control study. BMJ 2006, 333(7571):726.
6. Hansen M.L., Sørensen R., Clausen M.T., Fog-Petersen M.L., Raunsø J., Gadsbøll N., et al. Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. Arch Intern Med 2010, 13; 170(16):1433-1441.
7. Ageno W., Gallus A.S., Wittkowsky A., Crowther M., Hylek E.M., Palareti G., et al. Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012, 141(2 Suppl):e44S-e88S.
8. Schulman S., Beyth R.J., Kearon C., Levine M.N. Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2008, 133:257S-298S.
9. Choudhry N.K., Soumerai S.B., Normand S.L.T., Ross-Degnan D., Laupacis A., Anderson G.M. Warfarin prescribing in atrial fibrillation: the impact of physician, patient, and hospital characteristics. Am J Med 2006, 119:607-615.
10. Marcucci M., Iorio A., Nobili A., Tettamanti M., Pasina L., Djade C.D., et al. Mannucci PM; REPOSI Investigators. Prophylaxis of venous thromboembolism in elderly patients with multimorbidity. Intern Emerg Med 2013, 8:509-520.
11. Rubin T., Murdoch M., Nelson D.B. Acute GI bleeding in the setting of supratherapeutic international normalized ratio in patients taking warfarin: endoscopic diagnosis, clinical management, and outcomes. Gastrointest Endosc 2003, 58:369-373.
12. Wallentin L., Yusuf S., Ezekowitz M.D., Alings M., Flather M., Franzosi M.G., et al. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet 2010, 376:975-983.
13. De Caterina R., Husted S., Wallentin L., Andreotti F., Arnesen H., Bachmann F., et al. New oral anticoagulants in atrial fibrillation and acute coronary syndromes: ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease position paper. J Am Coll Cardiol 2012, 59:1413-1425.
14. Jacobs L.G. Warfarin pharmacology, clinical management, and evaluation of hemorrhagic risk for the elderly. Cardiol Clin 2008, 26(2):157-167.
15. Chan N.C., Paikin J.S., Hirsh J., Lauw M.N., Eikelboom J.W., Ginsberg J.S. New oral anticoagulants for stroke prevention in atrial fibrillation: impact of study design, double counting and unexpected findings on interpretation of study results and conclusions. Thromb Haemost 2014, 111(5):798-807.
16. Wann L.S., Curtis A.B., Ellenbogen K.A., Estes N.A., Ezekowitz M.D., Jackman W.M., et al. Management of patients with atrial fibrillation (compilation of 2006 ACCF/AHA/ESC and 2011 ACCF/AHA/HRS recommendations): a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines. Circulation 2013, 127(18):1916-1926.
17. Di Minno G., Ricciardi E., Scalera A. Laboratory tests during direct oral anticoagulant treatment? No. Intern Emerg Med 2013, 8(5):367-370.
18. Ruff C.T., Giugliano R.P., Braunwald E., Hoffman E.B., Deenadayalu N., Ezekowitz M.D., et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 2014, 383(9921):955-962.
19. Neumann I., Rada G., Claro J.C., Carrasco-Labra A., Thorlund K., Akl E.A., et al. Oral direct factor Xa inhibitors versus low-molecular-weight heparin to prevent venous thromboembolism in patients undergoing total hip or knee replacement: a systematic review and meta-analysis. Ann Intern Med 2012, 156:710-719.
20. Holster I.L., Valkhoff V.E., Kuipers E.J., Tjwa E.T. New oral anticoagulants increase risk for gastrointestinal bleeding: a systematic review and meta-analysis. Gastroenterology 2013, 145. [105-112.e15].
21. Yusuf S., Mehta S.R., Chrolavicius S., Afzal R., Pogue J., Granger C.B., et al. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med 2006, 354:1464-1476.
22. Eikelboom J.W., Mehta S.R., Anand S.S., Xie C., Fox K.A., Yusuf S. Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation 2006, 114:774-782.
23. Yusuf S., Zhao F., Mehta S.R., Chrolavicius S., Tognoni G., Fox K.K. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001, 345:494-502.
24. Schelleman H., Brensinger C.M., Bilker W.B., Hennessy S. Antidepressant-warfarin interaction and associated gastrointestinal bleeding risk in a case-control study. PLoS ONE 2011, 6(6):e21447.
25. White R.H., McKittrick T., Takakuwa J., Callahan C., McDonell M., Fihn S. National Consortium of Anticoagulation Clinics. Management and prognosis of life threatening bleeding during warfarin therapy. Arch Intern Med 1996, 156(11):1197-1201.
26. Kearon C., Hirsh J. Management of anticoagulation before and after elective surgery. N Engl J Med 1997, 336(21):1506-1511.
27. Rubin T.A., Murdoch M., Nelson D.B. Acute GI bleeding in the setting of supratherapeutic international normalized ratio in patients taking warfarin: endoscopic diagnosis, clinical management, and outcomes. Gastrointest Endosc 2003, 58(3):369-373.
28. Van der Meer F.J.M., Rosendaal F.R., Vandenbroucke J.P., Briet E. Bleeding complications in oral anticoagulant therapy: an analysis of risk factors. Arch Intern Med 1993, 153:1557-1562.
29. Landefeld C.S., Beyth R.J. Anticoagulant-related bleeding: clinical epidemiology, prediction, and prevention. Am J Med 1993, 95(3):315-328.
30. Choudari C.P., Palmer K.R. Acute gastrointestinal haemorrhage in patients treated with anticoagulant drugs. Gut 1995, 36:483-484.
31. Landefeld C.S., Cook E.F., Flatley M., Weisberg M., Goldman L. Identification and preliminary validation of predictors of major bleeding in hospitalized patients starting anticoagulant therapy. Am J Med 1987, 82:703-713.
32. Coleman C.I., Sobieraj D.M., Winkler S., Cutting P., Mediouni M., Alikhanov S., et al. Effect of pharmacological therapies for stroke prevention on major gastrointestinal bleeding in patients with atrial fibrillation. Int J Clin Pract 2012, 66:53-63.
33. Fang M.C., Chang Y., Hylek E.M., Rosand J., Greenberg S.M., Go A.S., et al. Advanced age, anticoagulation intensity, and risk for intracranial hemorrhage among patients taking warfarin for atrial fibrillation. Ann Intern Med 2004, 14:745-752.
34. Fihn S.D., Callahan C.M., Martin D.C., McDonell M.B., Henikoff J.G., White R.H. The risk for and severity of bleeding complications in elderly patients treated with warfarin. Ann Intern Med 1996, 124:970-979.
35. Poli D., Antonucci E., Testa S., Tosetto A., Ageno W., Palareti G., et al. Bleeding risk in very old patients on vitamin K antagonist treatment: results of a prospective collaborative study on elderly patients followed by Italian Centres for anticoagulation. Circulation 2011, 124:824-829.
36. Mant J., Hobbs R., Fletcher K., Roalfe A., Fitzmaurice D., Lip G.Y., et al. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (BAFTA): a randomized controlled trial. Lancet 2007, 370:493-503.
37. Eikelboom J.W., Wallentin L., Connolly S.J., Ezekowitz M., Healey J.S., Oldgren J., et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation 2011, 123:2363-2372.
38. Lim Y.J., Yang C.-H. Non-steroidal anti-inflammatory drug-induced enteropathy. Clin Endosc 2012, 45:138-144.
39. FDA Advisory Committee Briefing Document Boehringer Ingelheim. Dabigatran etexilate 2010, 1-168.
40. Dans A.L., Connolly S.J., Wallentin L., Yang S., Nakamya J., Brueckmann M., et al. Concomitant Use of Antiplatelet Therapy with Dabigatran or Warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Trial. Circulation 2013, 127:634-640.
41. Reilly P.A., Lehr T., Haertter S., Connolly S.J., Yusuf S., Eikelboom J.W., et al. The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy). J Am Coll Cardiol 2014, 63(4):321-328.
42. Bytzer P., Connolly S.J., Yang S., Ezekowitz M., Formella S., Reilly P.A., et al. Analysis of upper gastrointestinal adverse events among patients given dabigatran in the RE-LY trial. Clin Gastroenterol Hepatol 2013, 11(3). [246-52.e1-5].
43. Goodman S.G., Wojdyla D.M., Piccini J.P., White H.D., Paolini J.F., Nessel C.C., et al. Factors associated with major bleeding events: insights from the ROCKET AF trial (rivaroxaban once-daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation). J Am Coll Cardiol 2014, 63(9):891-900.
44. Hylek E.M., Held C., Alexander J.H., Lopes R.D., De Caterina R., Wojdyla D.M., et al. Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin: The ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation): Predictors, Characteristics, and Clinical Outcomes. J Am Coll Cardiol 2014, 63(20):2141-2147.
45. Levi M., Hovingh G.K., Cannegieter S.C., Vermeulen M., Büller H.R., Rosendaal F.R. Bleeding in patients receiving vitamin K antagonists who would have been excluded from trials on which the indication for anticoagulation was based. Blood 2008, 111:4471-4476.
46. Graham D.J., Reichman M.E., Wernecke M., Zhang R., Southworth M.R., Levenson M., et al. Cardiovascular, bleeding, and mortality risks in elderly medicare patients treated with dabigatran or warfarin for non-valvular atrial fibrillation. Circulation 2015, 131(2):157-164.
47. Garcia Rodriguez L.A., Hernández-Díaz S., de Abajo F.J. Association between aspirin and upper gastrointestinal complications: systematic review of epidemiologic studies. Br J Clin Pharmacol 2001, 52:563-571.
48. Albeldawi M., Qadeer M.A., Vargo J.J. Managing acute upper GI bleeding, preventing recurrences. Cleve Clin J Med 2010, 77:131-142.
49. Ridker P.M., Cook N.R., Lee I.M., Gordon D., Gaziano J.M., Manson J.E., et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 2005, 352:1293-1304.
50. Glynn R.J., Ridker P.M., Goldhaber S.Z., Buring J.E. Effect of low-dose aspirin on the occurrence of venous thromboembolism: a randomized trial. Ann Intern Med 2007, 147:525-533.
51. De Berardis G., Lucisano G., D'Ettorre A., Pellegrini F., Lepore V., Tognoni G., et al. Association of aspirin use with major bleeding in patients with and without diabetes. JAMA 2012, 307:2286-2294.
52. Sostres C., Gargallo C.J., Lanas A. Nonsteroidal anti-inflammatory drugs and upper and lower gastrointestinal mucosal damage. Arthritis Res Ther 2013, 15(Suppl. 3):S3.
53. Lanas A., Wu P., Medin J., Mills E.J. Low doses of acetylsalicylic acid increase risk of gastrointestinal bleeding in a meta-analysis. Clin Gastroenterol Hepatol 2011, 9(9):762-768.e6.
54. McQuaid K.R., Laine L. Systematic review and meta-analysis of adverse events of low-dose aspirin and clopidogrel in randomized controlled trials. Am J Med 2006, 119:624-638.
55. Bhatt D.L., Scheiman J., Abraham N.S., et al. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol 2008, 52:1502-1517.
56. Wolff T., Miller T., Ko S. Aspirin for the primary prevention of cardiovascular events: an update of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2009, 150:405-410.
57. Hernández-Díaz S., García Rodríguez L.A. Cardioprotective aspirin users and their excess risk of upper gastrointestinal complications. BMC Med 2006, 4:22.
58. Hsiao F.Y., Tsai Y.W., Huang W.F., Wen Y.W., Chen P.F., Chang P.Y., et al. A comparison of aspirin and clopidogrel with or without proton pump inhibitors for the secondary prevention of cardiovascular events in patients at high risk for gastrointestinal bleeding. Clin Ther 2009, 31(9):2038-2047.
59. Yuhara H., Corley D.A., Nakahara F., Nakajima T., Koike J., Igarashi M., et al. Aspirin and non-aspirin NSAIDs increase risk of colonic diverticular bleeding: a systematic review and meta-analysis. J Gastroenterol 2014, 49(6):992-1000.
60. Strate L.L., Liu Y.L., Huang E.S., Giovannucci E.L., Chan A.T. Use of aspirin or nonsteroidal anti-inflammatory drugs increases risk for diverticulitis and diverticular bleeding. Gastroenterology 2011, 140(5):1427-1433.
61. Lin C.C., Hu H.Y., Luo J.C., Peng Y.L., Hou M.C., Lin H.C., et al. Risk factors of gastrointestinal bleeding in clopidogrel users: a nationwide population-based study. Aliment Pharmacol Ther 2013, 38(9):1119-1128.
62. Connolly S.J., Pogue J., Hart R.G., Hohnloser S.H., Pfeffer M., Chrolavicius S., et al. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med 2009, 360:2066-2078.
63. Sørensen R., Hansen M.L., Abildstrom S.Z., Hvelplund A., Andersson C., Jørgensen C., et al. Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data. Lancet 2009, 374(9706):1967-1974.
64. García Rodríguez L.A., Lin K.J., Hernández-Díaz S., Johansson S. Risk of upper gastrointestinal bleeding with low-dose acetylsalicylic acid alone and in combination with clopidogrel and other medications. Circulation 2011, 123(10):1108-1115.
65. Lamberts M., Olesen J.B., Ruwald M.H., Hansen C.M., Karasoy D., Kristensen S.L., et al. Bleeding after initiation of multiple antithrombotic drugs, including triple therapy, in atrial fibrillation patients following myocardial infarction and coronary intervention: a nationwide cohort study. Circulation 2012, 126(10):1185-1193.
66. Di Minno M.N., Guida A., Camera M., Colli S., Minno G., Tremoli E. Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention. Ann Med 2011, 43(7):531-544.
67. Wiviott S.D., Braunwald E., McCabe C.H., Montalescot G., Ruzyllo W., Gottlieb S., et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007, 357:2001-2015.
68. Wallentin L., Becker R.C., Budaj A., Cannon C.P., Emanuelsson H., Held C., et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009, 361(11):1045-1057.
69. DiNicolantonio J.J., D'Ascenzo F., Tomek A., Chatterjee S., Niazi A.K., Biondi-Zoccai G. Clopidogrel is safer than ticagrelor in regard to bleeds: a closer look at the PLATO trial. Int J Cardiol 2013, 168(3):1739-1744.
70. Serebruany V.L. Aggressive chronic platelet inhibition with prasugrel and increased cancer risks: revising oral antiplatelet regimens?. Fundam Clin Pharmacol 2009, 23(4):411-417.
71. Nikolsky E., Stone G.W., Kirtane A.J., Dangas G.D., Lansky A.J., McLaurin B., et al. Gastrointestinal bleeding in patients with acute coronary syndromes: incidence, predictors, and clinical implications: analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial. J Am Coll Cardiol 2009, 54(14):1293-1302.
72. Mehran R., Pocock S.J., Stone G.W., Clayton T.C., Dangas G.D., Feit F., et al. Associations of major bleeding and myocardial infarction with the incidence and timing of mortality in patients presenting with non-ST-elevation acute coronary syndromes: a risk model from the ACUITY trial. Eur Heart J 2009, 30:1457-1466.
73. Rao S.V., O'Grady K., Pieper K.S., Granger C.B., Newby L.K., Van de Werf F., et al. Impact of bleeding severity on clinical outcomes among patients with acute coronary syndromes. Am J Cardiol 2005, 96:1200-1206.
74. Spencer F.A., Moscucci M., Granger C.B., Gore J.M., Goldberg R.J., Steg P.G., et al. Does comorbidity account for the excess mortality in patients with major bleeding in acute myocardial infarction?. Circulation 2007, 11; 116(24):2793-2801.
75. Lip G.Y.H. Recommendations for thromboprophylaxis in the 2012 focused update of the ESC guidelines on atrial fibrillation: a commentary. J Thromb Haemost 2013, 11:615-626.
76. Camm A.J., Lip G.Y., De Caterina R., Savelieva I., Atar D., Hohnloser S.H., et al. Document Reviewers. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation - developed with the special contribution of the European Heart Rhythm Association. Europace 2012, 14:1385-1413.
77. Omran H., Bauersachs R., Rubenacker S., Goss F., Hammerstingl C. The HAS-BLED score predicts bleedings during bridging of chronic oral anticoagulation. Results from the national multicentre BNK Online bRiDging REgistRy (BORDER). Thromb Haemost 2012, 108:65-73.
78. Smith J.G., Wieloch M., Koul S., Braun O.O., Lumsden J., Rydell E., et al. Triple antithrombotic therapy following an acute coronary syndrome: prevalence, outcomes and prognostic utility of the HAS-BLED score. EuroIntervention 2012, 8:672-678.
79. Lip G.Y., Nieuwlaat R., Pisters R., Lane D.A., Crijns H.J. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro heart survey on atrial fibrillation. Chest 2010, 137:263-272.
80. Schulman S., Eelde A., HolmströmM Ståhlberg G., Odeberg J., Blombäck M. Validation of a composite score for clinical severity of hemophilia. J Thromb Haemost 2008, 6:1113-1121.
81. Schiele F., van Ryn J., Canada K., Newsome C., Sepulveda E., Park J., et al. A specific antidote for dabigatran: functional and structural characterization. Blood 2013, 121(18):3554-3562.
82. Lu G., DeGuzman F.R., Hollenbach S.J., Karbarz M.J., Abe K., Lee G., et al. A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa. Nat Med 2013, 19(4):446-451.
83. Cavallaro L.G., Monica F., Germanà B., Marin R., Sturniolo G.C., Saia M. Time trends and outcome of gastrointestinal bleeding in the Veneto Region: a retrospective population based study from 2001 to 2010. Dig Liver Dis 2014, 46(4):313-317.
84. Lanas A., García-Rodríguez L.A., Polo-Tomás M., Ponce M., Quintero E., Perez-Aisa M.A., et al. The changing face of hospitalisation due to gastrointestinal bleeding and perforation. Aliment Pharmacol Ther 2011, 33(5):585-591.
85. Lanas A., García-Rodríguez L.A., Arroyo M.T., Bujanda L., Gomollón F., Forné M., et al. Effect of antisecretory drugs and nitrates on the risk of ulcer bleeding associated with nonsteroidal anti-inflammatory drugs, antiplatelet agents, and anticoagulants. Am J Gastroenterol 2007, 102:507-515.
86. Cea Soriano L., Rodríguez L.A. Risk of upper gastrointestinal bleeding in a cohort of new users of low-dose aspirin for secondary prevention of cardiovascular outcomes. Front Pharmacol 2010, 1:126.
87. Lin K.J., Hernándezdíaz S., García Rodríguez L.A. Acid suppressants reduce risk of gastrointestinal bleeding in patients on antithrombotic or anti-inflammatory therapy. Gastroenterology 2011, 141(1):71-79.
88. Barkun A.N., Bardou M., Kuipers E.J., Sung J., Hunt R.H., Martel M., et al. International consensus recommendations on the management of patients with nonvariceal upper gastrointestinal bleeding. Ann Intern Med 2010, 152:101-113.
89. Paré G., Eriksson N., Lehr T., Connolly S., Eikelboom J., Ezekowitz M.D., et al. Genetic determinants of dabigatran plasma levels and their relation to bleeding. Circulation 2013, 127(13):1404-1412.
90. Salazar D.E., Mendell J., Kastrissios H., Green M., Carrothers T.J., Song S., et al. Modelling and simulation of edoxaban exposure and response relationships in patients with atrial fibrillation. Thromb Haemost 2012, 107(5):925-936.
91. Song S., Kang D., Halim A.B., Miller R. Population pharmacokinetic-pharmacodynamic modeling analysis of intrinsic FXa and bleeding from edoxaban treatment. J Clin Pharmacol 2014, 54(8):910-916.
92. Calvin A.D., Aggarwal N.R., Murad M.H., Shi Q., Elamin M.B., Geske J.B., et al. Aspirin for the primary prevention of cardiovascular events: a systematic review and meta-analysis comparing patients with and without diabetes. Diabetes Care 2009, 32:2300-2306.
93. Baigent C., Blackwell L., Collins R., Emberson J., Godwin J., et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative metaanalysis of individual participant data from randomised trials. Lancet 2009, 373:1849-1860. Antithrombotic Trialists' (ATT) Collaboration.
94. Patrono C. Low-dose aspirin in primary prevention: cardioprotection, chemoprevention, both, or neither?. Eur Heart J 2013, 34(44):3403-3411.
95. Cea Soriano L., Bueno H., Lanas A., García Rodríguez L.A. Cardiovascular and upper gastrointestinal bleeding consequences of low-dose acetylsalicylic acid discontinuation. Thromb Haemost 2013, 110:1298-1304.
96. Dewilde W.J., Oirbans T., Verheugt F.W., Kelder J.C., De Smet B.J., Herrman J.P., et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet 2013, 30(381):1107-1115.
97. Huber K., Airaksinen K.J., Cuisset T., Marin F., Rubboli A., Lip G.Y. Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting: similarities and dissimilarities between North America and Europe. Thromb Haemost 2011, 106:569-571.
98. Cole A.T., Hudson N., Liew L.C., Murray F.E., Hawkey C.J., Heptinstall S. Protection of human gastric mucosa against aspirin-enteric coating or dose reduction?. Aliment Pharmacol Ther 1999, 13:187-193.
99. Witt D.M., Delate T., Garcia D.A., Clark N.P., Hylek E.M., Ageno W., et al. Risk of thromboembolism, recurrent hemorrhage, and death after warfarin interruption for gastrointestinal bleeding. Arch Intern Med 2012, 172(19):1484-1491.